ClinicalTrials.gg
CompletedNCT02943239Updated Aug 9, 2024

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

A Phase 1 interventional study of REGN1033 and REGN2477 in Healthy Volunteers, sponsored by Regeneron Pharmaceuticals. Completed at 2 sites in New Zealand. Open to participants aged 35 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
35 Years to 70 Years
Sex
All
01

Study summary

The primary objective is to assess the safety and tolerability of REGN2477 alone and combined with REGN1033.

The secondary objectives are to:

  • Assess the effect of REGN2477 alone, REGN1033 alone, and REGN2477 + REGN1033 in combination on thigh muscle volume
  • Assess the effects of REGN2477 alone, REGN1033 alone, and REGN2477 + REGN1033 in combination on total and regional body composition
  • Evaluate the Pharmacokinetic (PK) profile of REGN2477 and REGN1033
  • Assess immunogenicity of REGN2477 or REGN1033
  • Assess REGN2477 or REGN1033 target engagement
02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • women age 45 to 70 years and age 35 to 60 years inclusive for men not intending to father children
  • between 18 to 32 kg/m2, inclusive
  • Willing and able to maintain current diet, supplements and physical activity level throughout the study
  • Provides signed

Key Exclusion Criteria:

  • Significant illness or history of significant illness
  • to MRI
  • History of (HIV); or virus (HCV)
  • History of immobilization, major surgical procedure, fracture, or major trauma within 9 months prior to screening
  • History of significant gynecological disorders or ; history of breast malignancies (uterine fibroids or dysfunctional uterine bleeding is acceptable)
  • Inconsistent vigorous physical activity (on fewer than 5 days per week), such as intermittent weight lifting
  • History of reactions to tetracycline antibiotics (includes doxycycline), vaccines, or biologics
  • Use of agents that alter muscle mass that have not been at a stable dose for 3 months prior to screening (includes protein supplements), or use of any weight altering or anabolic steroid drugs (includes drugs for obesity, diuretics, testosterone)
  • Participants treated with a biologic therapy or biologic immunotherapy in the previous 12 weeks prior to screening and during the study

Note: Other protocol Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Panel A

    REGN1033 + REGN2477 (Regimen 1) or placebo

    Drug: REGN1033 · Drug: REGN2477 · Other: Placebo

  • Experimental
    Panel B

    Panel B - REGN1033 + REGN2477 (Regimen 2) or Placebo

    Drug: REGN1033 · Drug: REGN2477 · Other: Placebo

  • Experimental
    Panel C

    Panel C - Patients will receive either REGN1033 + REGN2477 (Regimen 3) or Placebo

    Drug: REGN1033 · Drug: REGN2477 · Other: Placebo

  • Experimental
    Panel D

    Panel D - Patients will receive either REGN1033 + REGN2477 (Regimen 4), REGN1033, REGN2477 (high dose) or Placebo

    Drug: REGN1033 · Drug: REGN2477 · Other: Placebo

  • Experimental
    Panel E

    REGN2477 (Regimen 5) or placebo

    Drug: REGN2477 · Other: Placebo

  • Experimental
    Panel F

    REGN2477 + REGN1033 (Regimen 6) or placebo

    Drug: REGN1033 · Drug: REGN2477 · Other: Placebo

  • Experimental
    Panel G

    REGN2477 (Regimen 7) or placebo

    Drug: REGN2477 · Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 40 weeks

Secondary outcomes

  1. Percent change in thigh muscle volume as measured by MRI

    Time frame: Up to 28 weeks

  2. Change in thigh muscle volume as measured by MRI

    Time frame: Up to 28 weeks

  3. Percent change in total and regional body composition as measured by Dual X-ray absorptiometry (DXA)

    Time frame: Up to 28 weeks

  4. Change in total body composition as measured by DXA

    Time frame: Up to 28 weeks

  5. Change in regional body composition as measured by DXA

    Time frame: Up to 28 weeks

  6. Pharmacokinetic profile of REGN2477 assessed via measurement of concentrations of REGN2477 in serum over time

    Time frame: Up to 40 weeks

  7. Pharmacokinetic profile of REGN1033 assessed via measurement of concentrations of REGN1033 in serum overtime

    Time frame: Up to 40 weeks

  8. Change in total Activin A levels in blood

    Time frame: Up to 40 weeks

  9. Change in total GDF8 levels in blood

    Time frame: Up to 32 weeks

  10. Presence or absence of antibodies against REGN2477 and REGN1033

    Time frame: Up to 40 weeks

07

Study locations

2 sites
  • Auckland, New Zealand
  • Christchurch, New Zealand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Apr 2019, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2016
First posted
Oct 24, 2016
StartActual
Dec 8, 2016
Primary completionActual
Apr 30, 2019
CompletionActual
Apr 30, 2019
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02943239
Responsible party
Sponsor
First posted
Oct 24, 2016
Start date
Dec 8, 2016
Primary completion
Apr 30, 2019
Completion
Apr 30, 2019
Last update
Aug 9, 2024

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trevogrumab · Garetosmab

Start the discussion